Suppr超能文献

小分子α-突触核蛋白聚集物 FN075 增强亚临床 AAV 大鼠模型中的α-突触核蛋白病理学。

The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models.

机构信息

Pharmacology & Therapeutics and Galway Neuroscience Centre, National University of Ireland Galway, H91 W5P7 Galway, Ireland.

Department of Chemistry, Umeå University, 901 87 Umeå, Sweden.

出版信息

Biomolecules. 2021 Nov 12;11(11):1685. doi: 10.3390/biom11111685.

Abstract

Animal models of Parkinson's disease, in which the human α-synuclein transgene is overexpressed in the nigrostriatal pathway using viral vectors, are widely considered to be the most relevant models of the human condition. However, although highly valid, these models have major limitations related to reliability and variability, with many animals exhibiting pronounced α-synuclein expression failing to demonstrate nigrostriatal neurodegeneration or motor dysfunction. Therefore, the aim of this study was to determine if sequential intra-nigral administration of AAV-α-synuclein followed by the small α-synuclein aggregating molecule, FN075, would enhance or precipitate the associated α-synucleinopathy, nigrostriatal pathology and motor dysfunction in subclinical models. Rats were given unilateral intra-nigral injections of AAV-α-synuclein (either wild-type or A53T mutant) followed four weeks later by a unilateral intra-nigral injection of FN075, after which they underwent behavioral testing for lateralized motor functionality until they were sacrificed for immunohistological assessment at 20 weeks after AAV administration. In line with expectations, both of the AAV vectors induced widespread overexpression of human α-synuclein in the substantia nigra and striatum. Sequential administration of FN075 significantly enhanced the α-synuclein pathology with increased density and accumulation of the pathological form of the protein phosphorylated at serine 129 (pS129-α-synuclein). However, despite this enhanced α-synuclein pathology, FN075 did not precipitate nigrostriatal degeneration or motor dysfunction in these subclinical AAV models. In conclusion, FN075 holds significant promise as an approach to enhancing the α-synuclein pathology in viral overexpression models, but further studies are required to determine if alternative administration regimes for this molecule could improve the reliability and variability in these models.

摘要

帕金森病动物模型中,通过病毒载体在黑质纹状体通路上过表达人α-突触核蛋白,被广泛认为是最接近人类疾病状况的模型。然而,尽管这些模型具有高度的有效性,但它们存在与可靠性和可变性相关的重大局限性,许多表现出明显α-突触核蛋白表达的动物未能显示黑质纹状体神经退行性变或运动功能障碍。因此,本研究旨在确定是否通过连续向黑质内注射 AAV-α-突触核蛋白,然后再注射小α-突触核蛋白聚集分子 FN075,可增强或加剧亚临床模型中与α-突触核蛋白病、黑质纹状体病理学和运动功能障碍相关的病变。将大鼠单侧黑质内注射 AAV-α-突触核蛋白(野生型或 A53T 突变体),四周后单侧黑质内注射 FN075,然后进行侧化运动功能测试,直到 AAV 给药后 20 周处死,进行免疫组织化学评估。正如预期的那样,两种 AAV 载体都在黑质和纹状体中诱导了广泛的人α-突触核蛋白过表达。FN075 的序贯给药显著增强了α-突触核蛋白病理学,增加了磷酸化丝氨酸 129 位的病理性蛋白(pS129-α-突触核蛋白)的密度和积累。然而,尽管存在这种增强的α-突触核蛋白病理学,FN075 并没有在这些亚临床 AAV 模型中引发黑质纹状体变性或运动功能障碍。总之,FN075 作为一种增强病毒过表达模型中α-突触核蛋白病理学的方法具有很大的潜力,但需要进一步的研究来确定这种分子的替代给药方案是否可以提高这些模型的可靠性和可变性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/582f/8615715/f8f096bda73c/biomolecules-11-01685-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验